vorapaxar sulfat - matokeo ya utafutaji kwa

Afrika Kusini - Kiingereza - South African Health Products Regulatory Authority (SAHPRA)

dupirta granules

viatris healthcare (pty) ltd - granules - 40,0 mg & 10,0 mg - each sachet contains lopinavir 40,0 mg ritonavir 10,0 mg

Afrika Kusini - Kiingereza - South African Health Products Regulatory Authority (SAHPRA)

pefrilo granules

viatris healthcare (pty) ltd - granules - 40,0 mg & 10,0 mg - each sachet contains lopinavir 40,0 mg ritonavir 10,0 mg

Afrika Kusini - Kiingereza - South African Health Products Regulatory Authority (SAHPRA)

grapitova granules

viatris healthcare (pty) ltd - granules - 40,0 mg & 10,0 mg - each sachet contains lopinavir 40,0 mg ritonavir 10,0 mg

Singapoo - Kiingereza - HSA (Health Sciences Authority)

sporanox oral solution 10 mgml

johnson & johnson international (singapore) pte ltd - itraconazole - solution - 10 mg/ml - itraconazole 10 mg/ml

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

itracap itraconazole 100 mg capsule blister pack

arrotex pharmaceuticals pty ltd - itraconazole, quantity: 100 mg - capsule - excipient ingredients: hypromellose; macrogol 20000; sucrose; hydrolysed maize starch; titanium dioxide; purified water; gelatin; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - itracap is indicated for use in adults for the treatment of: ? superficial dermatomycoses not responding to topical treatment. ? fungal keratitis which has failed to respond to topical treatment or where the disease is either progressing rapidly or is immediately sight threatening. ? pityriasis versicolor not responding to any other treatment. ? vulvovaginal candidiasis not responding to topical treatment. ? oral candidiasis in immunocompromised patients. ? onychomycosis caused by dermatophytes. ? systemic mycoses: - systemic aspergillosis, histoplasmosis, sporotrichosis. - treatment and maintenance therapy in aids patients with disseminated or chronic pulmonary histoplasmosis infection. - treatment of oropharyngeal and/or oesophageal candidiasis when first line systemic antifungal therapy is inappropriate or has proven ineffective. - treatment of non-invasive candidiasis in non-neutropenic patients when first-line systemic antifungal therapy is inappropriate or has proven ineffective. this may be due to underlying pathology, insensitivity of the pathogen or drug toxicity.